Acute Radiation Syndrome
, also known as radiation toxicity or radiation sickness, is an acute medical condition caused by irradiation of the whole body (or a significant portion of the body), by a high dose of penetrating radiation in a short period of time, generally minutes.
Cancer biotech company Partner Therapeutics Inc reported on Wednesday the receipt of the US FDA's approval for Leukine (sargramostim) for the treatment of adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome
, or H-ARS).
National Institutes of Health, in models of the acute radiation syndrome
The DOD is also studying the effectiveness of PLX-R18 as a novel medical countermeasure for Acute Radiation Syndrome
prior to exposure to high levels of radiation, designed to support the needs of the U.S.
M2 EQUITYBITES-June 7, 2018-Partner wins US FDA's approval for Leukine for treating Acute Radiation Syndrome
Pluristem is targeting several therapeutics indications for which clinical trials and preclinical studies are in progress, which include: intermittent claudication, muscle regeneration critical limb ischemia, Buerger's disease, and acute radiation syndrome
. The different studies are scheduled to take place in Europe, India, Israel and the U.S.
The study represents the first report of an effective radiation countermeasure for Acute Radiation Syndrome
(ARS) across a broad range of lethal radiation doses when administered as late as seven days after irradiation.
National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health, or NIH, has awarded a $2.5M grant to Indiana University to conduct studies of Pluristem's PLX-R18 cell therapy in the treatment of acute radiation syndrome
, or ARS.
Partner Therapeutics CEO, Robert Mulroy, said, 'The acquisition of Leukine provides us with an established commercial business, a product that has demonstrated a clear and substantial impact on outcomes, and a program with the potential to become a core component of immuno-oncology, the treatment of acute radiation syndrome
and the treatment of infections.'